| Treatment Category | Specific Treatment/Intervention | Mechanism of Action | Evidence Level | Outcome/Efficacy | Side Effects/Safety | Status | MAXO terms (suggested) |
|---|---|---|---|---|---|---|---|
| Ophthalmologic pharmacotherapy | Intravitreal anti-VEGF therapy (e.g., ranibizumab, bevacizumab, aflibercept class) | Inhibits VEGF-driven choroidal neovascularization secondary to breaks/calcification in Bruch’s membrane | Established clinical practice; supported by review-level clinical evidence (pqac-00000003, pqac-00000004, pqac-00000001) | Main symptomatic treatment for ophthalmic PXE; can prevent progression to hemorrhage/scarring and preserve central vision when CNV is treated promptly (pqac-00000003, pqac-00000004) | Standard intravitreal injection risks not detailed in retrieved contexts; no PXE-specific major safety signal highlighted in retrieved sources (pqac-00000003, pqac-00000004) | Standard-of-care symptomatic treatment; not disease-curative (pqac-00000003, pqac-00000004) | MAXO: anti-VEGF therapy; intravitreal injection; treatment of choroidal neovascularization |
| Anti-mineralization pharmacotherapy | Etidronate (cyclical oral bisphosphonate) | Stable pyrophosphate analog; inhibits hydroxyapatite crystal growth and ectopic mineralization | Randomized placebo-controlled clinical trial in PXE (n=74) (pqac-00000014) | Over 12 months, arterial calcification decreased 4% (IQR -11% to 7%) with etidronate versus increased 8% (IQR -1% to 20%) with placebo (p=0.001); fewer subretinal neovascularization events (1 vs 9; p=0.007) (pqac-00000014) | No major safety issues in trial; hyperphosphatemia in 48.6% vs 0% placebo, recovered spontaneously; hypocalcemia infrequent; bone density change not significantly different (pqac-00000014) | Investigational / off-label disease-modifying candidate; not specifically approved for PXE (pqac-00000014, pqac-00000000) | MAXO: bisphosphonate therapy; ectopic calcification prevention; oral drug administration |
| Anti-mineralization pharmacotherapy | Bisphosphonates (class concept beyond etidronate) | PPi analogs that inhibit calcium phosphate crystal formation/deposition | Preclinical + review evidence; class discussed as therapeutic strategy (pqac-00000017, pqac-00000015, pqac-00000000) | Considered promising because PXE is a PPi-deficiency disorder; strongest direct human evidence among class is etidronate trial (pqac-00000014, pqac-00000015) | Class-related safety issues not detailed in retrieved PXE contexts beyond etidronate findings (pqac-00000014) | Investigational / off-label in PXE (pqac-00000015, pqac-00000000) | MAXO: bisphosphonate therapy |
| Enzyme replacement / pathway restoration | INZ-701 (recombinant ENPP1) | Restores extracellular ENPP1 activity, raising plasma PPi by using circulating ATP substrate | Preclinical mouse study in Abcc6-/- PXE model (pqac-00000011) | Increased steady-state plasma ENPP1 activity and PPi; significantly reduced ectopic calcification in muzzle skin biomarker tissue after 8 weeks (pqac-00000011) | Human safety not available in retrieved PXE contexts; preclinical study supports therapeutic potential (pqac-00000011) | Preclinical / investigational for PXE (pqac-00000011) | MAXO: enzyme replacement therapy; recombinant protein therapy; pyrophosphate restoration |
| Nutritional / metabolic support | Magnesium supplementation / increased magnesium | May reduce calcification propensity by influencing mineral buffering and crystal formation; magnesium associated with higher T50 (calcification resistance) (pqac-00000010, pqac-00000015) | Biomarker association + review/preclinical rationale (pqac-00000010, pqac-00000015) | Not proven as definitive therapy in retrieved human PXE trials; biologically plausible adjunct because magnesium was a determinant of serum T50 (p=0.034) (pqac-00000010) | Specific PXE safety data not detailed in retrieved contexts (pqac-00000010, pqac-00000015) | Supportive / investigational adjunct (pqac-00000010, pqac-00000015) | MAXO: magnesium supplementation; dietary mineral supplementation |
| Lifestyle / risk reduction | Lifestyle modification and vascular risk-factor control | Reduces additive cardiovascular risk in a disease with arterial calcification/PAD and stroke risk | Review/guideline-style clinical recommendation (pqac-00000003, pqac-00000000, pqac-00000008) | Recommended as part of standard management; aimed at reducing vascular complications rather than reversing PXE (pqac-00000003, pqac-00000000) | Generally safe; details not quantified in retrieved contexts (pqac-00000003, pqac-00000000) | Standard supportive care (pqac-00000003, pqac-00000000) | MAXO: lifestyle modification; cardiovascular risk reduction; smoking avoidance; exercise counseling |
| Lipid-lowering / vascular prevention | Lipid-lowering measures | Addresses cardiovascular risk burden and possible dyslipidemia contribution | Review-level clinical recommendation (pqac-00000003, pqac-00000000, pqac-00000008) | Used to reduce vascular risk factors; not shown in retrieved contexts to reverse mineralization directly (pqac-00000003, pqac-00000000) | Drug-specific adverse effects not detailed in retrieved PXE contexts (pqac-00000003) | Supportive standard care when indicated (pqac-00000003) | MAXO: lipid-lowering therapy |
| Surgical / interventional vascular care | Vascular surgery / endovascular intervention for severe PAD or arterial lesions | Revascularization or treatment of advanced vascular stenosis/occlusion | Clinical practice / symptomatic management (pqac-00000003, pqac-00000000) | Reserved for severe cardiovascular manifestations; may be necessary in advanced stages of PAD (pqac-00000003, pqac-00000013) | Success may be affected by distal vessel involvement/calcification; careful vascular assessment recommended (pqac-00000006) | Standard symptomatic intervention when indicated (pqac-00000003) | MAXO: vascular surgery; endovascular procedure; peripheral revascularization |
| Dermatologic / cosmetic management | Management of skin lesions / cosmetic care | Addresses lax redundant skin and cosmetic burden rather than underlying metabolic defect | Review-level clinical experience (pqac-00000009, pqac-00000000) | Cutaneous findings are primarily cosmetic concern; treatment does not address systemic disease (pqac-00000004, pqac-00000009) | Safety depends on procedure; specific PXE data limited in retrieved contexts (pqac-00000009) | Supportive / symptomatic (pqac-00000009) | MAXO: dermatologic care; cosmetic intervention |
| Experimental small-molecule therapy | Minocycline | DDR/PARP1-modulating effects; proposed anticalcifying activity in PXE pathogenesis | Preclinical proof-of-concept in Abcc6-/- mice (pqac-00000011) | Oral minocycline reduced ectopic calcification by 43.4% (p<0.0001) in Abcc6-/- mice; supported by H2AX evidence of DDR activation at calcification sites (pqac-00000011) | Favorable human safety profile noted generally in paper abstract, but no PXE clinical safety data provided (pqac-00000011) | Preclinical / investigational repurposing candidate (pqac-00000011) | MAXO: tetracycline therapy; DNA-damage-response modulation |
| Experimental anti-crystallization therapy | SNF472 / CSL525 (hexasodium fytate) | Direct inhibitor of calcium phosphate crystallization | Preclinical animal studies (zebrafish, mouse, rat models) (pqac-00000014) | Reduced calcified area by ~40% in abcc6a-/- zebrafish larvae; inhibited muzzle calcification by 57% in abcc6-/- mice; inhibited rat skin calcification by 60% (pqac-00000014) | Human PXE safety not available in retrieved contexts (pqac-00000014) | Preclinical / investigational (pqac-00000014) | MAXO: calcification inhibitor therapy; phytate therapy |
| Gene-based therapy | Gene therapy / gene editing / liver-directed correction of ABCC6 | Restores ABCC6 function in liver, the main source of systemic anti-calcification signaling | Review/future perspective in PXE; preclinical direction supported broadly (pqac-00000003, pqac-00000000, pqac-00000015) | Considered a plausible future disease-modifying approach; no approved human PXE gene therapy in retrieved contexts (pqac-00000003, pqac-00000000) | Clinical safety not established for PXE in retrieved contexts (pqac-00000003) | Investigational / conceptual-preclinical (pqac-00000003, pqac-00000000) | MAXO: gene therapy; genome editing; liver-directed gene transfer |
| Pharmacologic chaperone strategy | Pharmacologic chaperone therapy for selected ABCC6 variants | Aims to rescue trafficking/function of misfolded but potentially rescuable ABCC6 protein | Review/future perspective (pqac-00000003, pqac-00000000) | Potentially useful for certain variant classes; no established clinical efficacy in retrieved contexts (pqac-00000003) | Safety unknown in PXE clinical practice from retrieved contexts (pqac-00000003) | Investigational / conceptual-preclinical (pqac-00000003) | MAXO: pharmacologic chaperone therapy |
| Supportive care / monitoring | Regular ophthalmologic, dermatologic, and vascular surveillance | Early detection and management of CNV, PAD, calcification progression, and complications | Standard clinical management supported by natural history/diagnostic literature (pqac-00000005, pqac-00000012, pqac-00000003) | Important because progression is chronic and age-dependent; enables timely anti-VEGF and vascular intervention (pqac-00000005, pqac-00000012, pqac-00000003) | Low procedural risk from surveillance itself; burden of repeated monitoring not quantified (pqac-00000005, pqac-00000012) | Standard supportive care (pqac-00000003, pqac-00000005) | MAXO: clinical surveillance; ophthalmologic monitoring; vascular monitoring |
| Biomarker-guided trial support | OCT Bruch’s membrane reflectivity; serum T50 as trial/monitoring biomarkers | Imaging/serum endpoints to quantify retinal calcification and systemic calcification propensity | Observational biomarker studies (pqac-00000012, pqac-00000010) | OCT RPE-BM peak reflectivity discriminated PXE from controls with AUC 0.85; shorter T50 associated with more severe ocular, vascular, and overall disease (pqac-00000012, pqac-00000010) | Biomarkers themselves are low-risk; clinical utility for routine treatment decisions still emerging (pqac-00000010, pqac-00000012) | Investigational as outcome measures / companion tools (pqac-00000010, pqac-00000012) | MAXO: biomarker monitoring; optical coherence tomography; serum assay monitoring |


*Table: This table summarizes current, investigational, and preclinical treatment strategies for pseudoxanthoma elasticum, including mechanisms, evidence strength, outcomes, safety considerations, and suggested MAXO mappings. It is useful for quickly comparing symptomatic care versus emerging disease-modifying approaches.*